Thousand Oaks, California
Amgen announced that it is working with the U.S. government on new measures aimed at lowering the cost of prescription medicines for patients in the United States, while continuing to invest in scientific innovation and domestic manufacturing. The company stated that its actions align with recent federal requests related to international reference pricing and patient affordability initiatives, though specific terms have not been publicly disclosed.
Amgen emphasized that the United States remains a global leader in biopharmaceutical innovation and said it plans to remain engaged with policymakers to ensure that innovation is supported while improving patient access to medicines.
As part of its affordability efforts, Amgen will expand its direct-to-patient access program, making additional medicines available at reduced monthly prices. The migraine prevention therapy Aimovig and the inflammatory disease treatment Amjevita will be offered at a discounted price of $299 per month, representing substantial reductions from their current list prices. These products join Repatha, a cholesterol-lowering therapy that was added to the program earlier this year at a reduced monthly cost.
The access program is available to eligible patients, including those without insurance, individuals enrolled in high-deductible health plans, and patients who prefer to pay out of pocket. The medicines included in the program will also be accessible through a federal prescription platform.
Amgen highlighted its continued commitment to U.S.-based investment, noting that it has spent more than $40 billion on manufacturing and research and development since 2018. The company recently announced an additional $2.5 billion in domestic manufacturing investments, including facility expansions in Ohio and North Carolina. Amgen stated that these investments support job creation, supply chain resilience, and long-term innovation in the United States.
The company added that its ongoing manufacturing commitments have been recognized through temporary relief from certain industry-specific tariffs.
Amgen is a global biotechnology company focused on discovering, developing, and delivering innovative medicines for patients with serious illnesses, including cancer, cardiovascular disease, inflammatory conditions, osteoporosis, and rare diseases. With more than four decades of experience in biotechnology, the company continues to advance a broad research pipeline while maintaining a significant manufacturing and innovation footprint in the United States.
By